Effect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients

Gabriele Fragasso, Altin Palloshi, Amarild Cuko

Research output: Contribution to journalArticle

Abstract

It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evaluated in patients with postischemic left ventricular dysfunction. Trimetazidine significantly improved both insulin-induced forearm oxidation of glucose and release of cyclic guanosine monophosphate, whereas forearm release of endothelin-1 was decreased. Although these findings need further confirmation, the combined beneficial effects of trimetazidine on left ventricular function and glucose metabolism make the use of this drug particularly attractive, especially in those cardiac patients in whom abnormalities of both myocardial and glucose metabolism coexist.

Original languageEnglish
JournalHeart and Metabolism
Issue number30
Publication statusPublished - 2006

Fingerprint

Trimetazidine
Coenzyme A
Forearm
Glucose
Left Ventricular Dysfunction
Cyclic GMP
Vasoconstrictor Agents
Endothelin-1
Vasodilator Agents
Lipid Metabolism
Left Ventricular Function
Fatty Acids
Insulin
Pharmaceutical Preparations

Keywords

  • 3-ketoacyl coenzyme A thiolase inhibition
  • Diabetes
  • Endothelial function
  • Glucose metabolism
  • Left ventricular function
  • Trimetazidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients. / Fragasso, Gabriele; Palloshi, Altin; Cuko, Amarild.

In: Heart and Metabolism, No. 30, 2006.

Research output: Contribution to journalArticle

@article{27cda7d3619945b8acfd6c3afdfbba5f,
title = "Effect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients",
abstract = "It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evaluated in patients with postischemic left ventricular dysfunction. Trimetazidine significantly improved both insulin-induced forearm oxidation of glucose and release of cyclic guanosine monophosphate, whereas forearm release of endothelin-1 was decreased. Although these findings need further confirmation, the combined beneficial effects of trimetazidine on left ventricular function and glucose metabolism make the use of this drug particularly attractive, especially in those cardiac patients in whom abnormalities of both myocardial and glucose metabolism coexist.",
keywords = "3-ketoacyl coenzyme A thiolase inhibition, Diabetes, Endothelial function, Glucose metabolism, Left ventricular function, Trimetazidine",
author = "Gabriele Fragasso and Altin Palloshi and Amarild Cuko",
year = "2006",
language = "English",
journal = "Heart and Metabolism",
issn = "1566-0338",
publisher = "Imprimerie Jouve",
number = "30",

}

TY - JOUR

T1 - Effect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients

AU - Fragasso, Gabriele

AU - Palloshi, Altin

AU - Cuko, Amarild

PY - 2006

Y1 - 2006

N2 - It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evaluated in patients with postischemic left ventricular dysfunction. Trimetazidine significantly improved both insulin-induced forearm oxidation of glucose and release of cyclic guanosine monophosphate, whereas forearm release of endothelin-1 was decreased. Although these findings need further confirmation, the combined beneficial effects of trimetazidine on left ventricular function and glucose metabolism make the use of this drug particularly attractive, especially in those cardiac patients in whom abnormalities of both myocardial and glucose metabolism coexist.

AB - It has recently been shown that trimetazidine, a 3-ketoacyl coenzyme A thiolase inhibitor, improves overall glucose metabolism in diabetic patients with left ventricular dysfunction. Forearm glucose and lipid metabolism and forearm release of endothelial vasodilator and vasoconstrictor factors during prolonged partial inhibition of fatty acid oxidation by trimetazidine have recently been evaluated in patients with postischemic left ventricular dysfunction. Trimetazidine significantly improved both insulin-induced forearm oxidation of glucose and release of cyclic guanosine monophosphate, whereas forearm release of endothelin-1 was decreased. Although these findings need further confirmation, the combined beneficial effects of trimetazidine on left ventricular function and glucose metabolism make the use of this drug particularly attractive, especially in those cardiac patients in whom abnormalities of both myocardial and glucose metabolism coexist.

KW - 3-ketoacyl coenzyme A thiolase inhibition

KW - Diabetes

KW - Endothelial function

KW - Glucose metabolism

KW - Left ventricular function

KW - Trimetazidine

UR - http://www.scopus.com/inward/record.url?scp=33745875640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745875640&partnerID=8YFLogxK

M3 - Article

JO - Heart and Metabolism

JF - Heart and Metabolism

SN - 1566-0338

IS - 30

ER -